Retrophin, LLC is a privately-held New York-based, biotechnology company focused on discovering and developing treatments for rare and life-threatening diseases. Retrophin is currently developing treatments for focal segmental glomerulosclerosis, Duchenne Muscular Dystrophy, spinal muscular atrophy, cystic fibrosis and myotubular myopathy.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/07/12 | $4,000,000 | Series A |
MSMB Capital | undisclosed |
